Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.
Capricor shares surged 67.22% after-hours: Q2 miss ($0.70 loss vs $0.58 estimate), zero revenue, $237.9M cash. Deramiocel BLA in FDA active review. Extreme oversold (RSI 16.47, down 45.89% YTD) signals speculative recovery play on regulatory catalyst.
Capricor Therapeutics Inc.
(NASDAQ:CAPR) shares are trending on Friday.
Shares of the clinical-stage biotechnology company climbed 67.22% to $7.04 after the bell on Thursday.
In the regular session, CAPR closed at $4.21, up 0.48%, according to Benzinga Pro data.
The stock saw elevated trading activity, with volume reaching 16.75 million shares, about 3.6 times its average daily volume of 4.64 million shares.
US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
CAPR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
